Health
Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test – News-Medical.net
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expan…

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.
Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the S…
-
Noosa News19 hours ago
How Lily Steele-Park took her rapist to court and won
-
Business22 hours ago
5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Business24 hours ago
Where will Nvidia stock be in 1 year?
-
General23 hours ago
Aboriginal policy vacuum from Liberals, Labor as NAIDOC Week starts